In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Outcomes for patients ...
Screening for Financial Toxicity and Health-Related Social Risks in Patients With GI Cancer: Results From a Large Cancer Center To better understand the priorities that guide patients with multiple ...
NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2026 Giants of Multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results